Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 2428

TitleReference numberPublishedLast updated
Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adultsIPG799
Tebentafusp for treating advanced uveal melanomaTA1027
Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasiaIPG798
Tirzepatide for managing overweight and obesityTA1026
Digital technologies to support self-management of COPD: early value assessmentHTE19
Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndromeDG62
MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson'sIPG796
MRI-guided focused ultrasound subthalamotomy for treating Parkinson'sIPG797
Ublituximab for treating relapsing multiple sclerosisTA1025
Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implantIPG795
Urinary tract infection (recurrent): antimicrobial prescribingNG112
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1023
Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal)TA1024
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA1021
Bevacizumab gamma for treating wet age-related macular degenerationTA1022
Meningitis (bacterial) and meningococcal diseaseQS19
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN)NG245
Eplontersen for treating hereditary transthyretin-related amyloidosisTA1020
Asthma pathway (BTS, NICE, SIGN)NG244
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosisTA1018
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and overTA1019
Endoscopic bipolar radiofrequency ablation for malignant biliary obstructionIPG794
Elafibranor for previously treated primary biliary cholangitisTA1016
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancerTA1014
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Endometriosis: diagnosis and managementNG73
Menopause: identification and managementNG23
Avapritinib for treating advanced systemic mastocytosisTA1012
Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devicesDG61
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuriaTA1010
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemiaTA1013
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD)DG60
Belzutifan for treating tumours associated with von Hippel-Lindau diseaseTA1011
Acute kidney injury: prevention, detection and managementNG148
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertensionTA1009
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatmentsTA1008
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancerTA1007
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1006
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overTA1002
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overTA1003
Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusionTA1004
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangementTA1005
Iptacopan for treating paroxysmal nocturnal haemoglobinuriaTA1000
Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatmentTA1001
Vibegron for treating symptoms of overactive bladder syndromeTA999
Single-step scaffold insertion for repairing symptomatic chondral knee defectsIPG793
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinomaTA997
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737

Results per page

  1. 10
  2. 25
  3. 50
  4. All